Results 11 to 20 of about 3,776 (143)

Observational Study of Talimogene Laherparepvec use for Melanoma in Clinical Practice in the United States (COSMUS-1)

Melanoma Management, 2019
Aim: Talimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine how T-VEC is used in US clinical practice.
John M Kirkwood, Robert Conry
exaly   +4 more sources

Observational Study Of Talimogene Laherparepvec Use in the Anti-PD-1 era for Melanoma in the US (COSMUS-2)

Melanoma Management, 2020
Aim: Talimogene laherparepvec (T-VEC) is an intralesional therapy for unresectable, metastatic melanoma. T-VEC real-world use in the context of anti-PD1-based therapy requires further characterization. Materials & methods: A retrospective review of T-VEC
Richard Carvajal, Elizabeth Buchbinder
exaly   +4 more sources

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Journal for ImmunoTherapy of Cancer, 2019
Background Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients with unresectable stage IIIB–IVM1c
Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling, Howard L. Kaufman   +6 more
doaj   +2 more sources

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab

Journal for ImmunoTherapy of Cancer, 2018
Background Immune-directed therapies have become front-line therapy for melanoma and are transforming the management of advanced disease. In refractory cases, multi-modal immunoncology (IO) approaches are being utilized, including combining immune ...
David M. Miller, Ryan M. Trowbridge, Anupam Desai, Reed E. Drews   +3 more
doaj   +2 more sources

Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC) [PDF]

Journal of Immunotherapy and Precision Oncology, 2018
Talimogene laherparepvec (T-VEC) is an intralesional oncolytic viral therapy for the treatment of recurrent, unresectable cutaneous, subcutaneous, and nodal melanoma.
Jennifer Gardner, Teresa Hyun, Gideon Steinbach, John Thompson   +3 more
doaj   +2 more sources

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma

Case Reports in Oncological Medicine, 2019
Talimogene laherparepvec is a novel, genetically engineered, oncolytic herpes virus approved for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.
Umang Swami, Brian Swick, Yousef Zakharia, Mohammed Milhem   +3 more
doaj   +2 more sources

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy [PDF]

Journal for ImmunoTherapy of Cancer, 2016
With the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place in the clinic. However, the adoption of T-VEC
Ann W. Silk, Howard L. Kaufman, Hasan Rehman, Michael P. Kane   +3 more
doaj   +2 more sources

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec [PDF]

JAAD Case Reports, 2023
Erin M. McClure, BS, Neha Singh, BS, Kim G. Abson, MD, MPH, Shailender Bhatia, MD, Heidi J. Gray, MD, Laura S. Brown, PhD, ABPP, Ata S. Moshiri, MD, MPH   +6 more
doaj   +2 more sources

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection [PDF]

JAAD Case Reports, 2022
Leonid Shmuylovich, MD, PhD, Aubriana M. McEvoy, MD, MS, Ryan C. Fields, MD, Leonel Hernandez-Aya, MD, George Ansstas, MD, David Y. Chen, MD, PhD   +5 more
doaj   +2 more sources

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec [PDF]

JAAD Case Reports, 2023
Jamie Lebhar, BME, Jennifer Jacobs, BS, Khushnood Faraz, BS, April K.S. Salama, MD, Paul J. Mosca, MD, PhD, MBA   +4 more
doaj   +2 more sources